Abstract
The present paper summarizes the results of a number of pharmacological studies implicating the cannabinoid CB1 receptor in the neural circuitry regulating different alcohol-related behaviors in rodents. Specifically, cannabinoid CB1 receptor antagonists - including the prototype, rimonabant - have been reported to suppress: (a) acquisition and maintenance of alcohol drinking behavior under the 2-bottle “alcohol vs water” choice regimen; (b) the increase in alcohol intake occurring after a period of alcohol abstinence (an experimental model of alcohol relapse); (c) alcohols reinforcing and motivational properties measured in rats trained to perform a specific task (e.g., lever-pressing) to access alcohol; (d) reinstatement of extinguished alcohol-seeking behavior triggered in rats by a nicotine challenge or presentation of cues previously associated to alcohol availability (another model of alcohol relapse). Additional data indicate that the opioid receptor antagonists, naloxone and naltrexone, synergistically potentiate the suppressing effect of rimonabant on alcohol intake and alcohols motivational properties in rats. Conversely, the two clinical studies conducted to date (one in alcoholdependent individuals and one in nontreatment-seeking heavy alcohol drinkers) yielded less conclusive results. Unfortunately, the recent discontinuation - due to the occurrence of some psychiatric adverse effects - of all trials with cannabinoid CB1 receptor antagonists apparently hinders further investigations on the potential of rimonabant in the treatment of alcohol dependence.
Keywords: Cannabinoid CB1 receptor antagonists, rimonabant, alcohol, animal models of alcoholism, alcohol relapse
CNS & Neurological Disorders - Drug Targets
Title: Blockade of the Cannabinoid CB1 Receptor and Alcohol Dependence: Preclinical Evidence and Preliminary Clinical Data
Volume: 9 Issue: 1
Author(s): Paola Maccioni, Giancarlo Colombo and Mauro A.M. Carai
Affiliation:
Keywords: Cannabinoid CB1 receptor antagonists, rimonabant, alcohol, animal models of alcoholism, alcohol relapse
Abstract: The present paper summarizes the results of a number of pharmacological studies implicating the cannabinoid CB1 receptor in the neural circuitry regulating different alcohol-related behaviors in rodents. Specifically, cannabinoid CB1 receptor antagonists - including the prototype, rimonabant - have been reported to suppress: (a) acquisition and maintenance of alcohol drinking behavior under the 2-bottle “alcohol vs water” choice regimen; (b) the increase in alcohol intake occurring after a period of alcohol abstinence (an experimental model of alcohol relapse); (c) alcohols reinforcing and motivational properties measured in rats trained to perform a specific task (e.g., lever-pressing) to access alcohol; (d) reinstatement of extinguished alcohol-seeking behavior triggered in rats by a nicotine challenge or presentation of cues previously associated to alcohol availability (another model of alcohol relapse). Additional data indicate that the opioid receptor antagonists, naloxone and naltrexone, synergistically potentiate the suppressing effect of rimonabant on alcohol intake and alcohols motivational properties in rats. Conversely, the two clinical studies conducted to date (one in alcoholdependent individuals and one in nontreatment-seeking heavy alcohol drinkers) yielded less conclusive results. Unfortunately, the recent discontinuation - due to the occurrence of some psychiatric adverse effects - of all trials with cannabinoid CB1 receptor antagonists apparently hinders further investigations on the potential of rimonabant in the treatment of alcohol dependence.
Export Options
About this article
Cite this article as:
Maccioni Paola, Colombo Giancarlo and Carai A.M. Mauro, Blockade of the Cannabinoid CB1 Receptor and Alcohol Dependence: Preclinical Evidence and Preliminary Clinical Data, CNS & Neurological Disorders - Drug Targets 2010; 9 (1) . https://dx.doi.org/10.2174/187152710790966623
DOI https://dx.doi.org/10.2174/187152710790966623 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is There a Relationship Between Sweet Taste and Seizures? Anticonvulsant and Proconvulsant Effects of Non-Nutritive Sweeteners
Combinatorial Chemistry & High Throughput Screening Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Transitional Age Youth with Serious Mental Illness: High Acuity Patients Requiring Developmentally Informed Care in the Inpatient Hospital Setting
Adolescent Psychiatry L-carnitine Supplementation Improves Self-rating Depression Scale Scores in Uremic Male Patients Undergoing Hemodialysis
Letters in Drug Design & Discovery Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Cancer Chemoprevention Drug Targets
Current Drug Targets Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Should we Try to Alleviate Immunosenescence and Inflammaging - Why, How and to What Extent?
Current Pharmaceutical Design Toll-like Receptor 4 Mediates LPS-Induced Release of Nitric Oxide and Tumor Necrosis Factor-α by Embryonal Cardiomyocytes: Biological Significance and Clinical Implications in Human Pathology
Current Pharmaceutical Design The Synergistic Cytotoxic and Apoptotic Effect of Resveratrol and Naringenin on Y79 Retinoblastoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Combinatorial Chemistry & High Throughput Screening Pros and Cons of the new DSM-5 Chapter of Obsessive-Compulsive and Related Disorders
Current Psychiatry Reviews Editorial: Mobile Technology and Naturalistic Study Designs in Addiction Research
Current Drug Abuse Reviews Differences Between Parkinson’s and Huntington’s Diseases and Their Role for Prioritization of Stem Cell-Based Treatments
Current Molecular Medicine An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology